2026-06-14T03:41:01Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/120882024-11-28T18:03:38Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16961

00925njm 22002777a 4500 dc Abdel-Mohsen, Mohamed author Richman, Douglas author Siliciano, Robert F author Nussenzweig, Michel C author Howell, Bonnie J author Martinez-Picado, Javier author Chomont, Nicolas author Bar, Katharine J author Yu, Xu G author Lichterfeld, Mathias author Alcamí, José author Hazuda, Daria author Bushman, Frederic author Siliciano, Janet D author Betts, Michael R author Spivak, Adam M author Planelles, Vicente author Hahn, Beatrice H author Smith, Davey M author Ho, Ya-Chi author Gaebler, Christian author Paiardini, Mirko author Li, Qingsheng author Estes, Jacob D author Hope, Thomas J author Kostman, Jay author Mounzer, Karam author Caskey, Marina author Fox, Lawrence author Frank, Ian author Riley, James L author Tebas, Pablo author Montaner, Luis J author Buzon, Maria J author 2020 Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will require a consensus on how best to measure the numbers of persistently infected cells with the potential to cause viral rebound after antiretroviral-therapy cessation in assessing the results of cure-directed strategies in vivo. Current measurements assess various aspects of the HIV provirus and its functionality and produce divergent results. Here, we provide recommendations from the BEAT-HIV Martin Delaney Collaboratory on which viral measurements should be prioritized in HIV-cure-directed clinical trials. Nat Med . 2020 Sep;26(9):1339-1350. 10.1038/s41591-020-1022-1 1546-170X Nature medicine 32895573 http://hdl.handle.net/20.500.12105/12088 HIV latency HIV reservoirs Viral measurements HIV Cure HIV persistence Replication-competent HIV Recommendations for measuring HIV reservoir size in cure-directed clinical trials.